Revolution Medicines financials
$204.48+1.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $11.6M | $35.4M | $29.4M | $43.0M |
| Gross profit | $0.00 | $0.00 | $11.6M | $35.4M | $29.4M | $43.0M |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$1.18B | -$689.5M | -$487.2M | -$258.3M | -$188.0M | -$110.7M |
| Net income | -$1.13B | -$600.1M | -$436.4M | -$248.7M | -$187.1M | -$110.4M |
| Net margin | — | — | −3768.3% | −703.0% | −636.6% | −256.8% |
| Diluted EPS | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 | $-2.01 |
| EBITDA | -$1.17B | -$681.9M | -$481.1M | -$253.2M | -$180.7M | -$104.2M |
| Operating cash flow | -$897.7M | -$557.4M | -$350.6M | -$224.4M | -$147.2M | -$100.1M |
| Free cash flow | -$913.7M | -$567.7M | -$358.3M | -$235.2M | -$153.7M | -$103.0M |
| Diluted shares | 190.1M | 167.7M | 113.1M | 80.6M | 72.8M | 54.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $383.7M | $543.1M | $696.1M | $161.4M | $108.5M | $104.3M |
| Short-term investments | $1.64B | $1.75B | $1.16B | $483.5M | $468.6M | $336.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $2.35B | $2.56B | $2.06B | $811.9M | $738.0M | $567.4M |
| Total liabilities | $723.2M | $293.1M | $235.5M | $126.7M | $135.4M | $92.7M |
| Shareholders' equity | $1.63B | $2.27B | $1.83B | $685.2M | $602.6M | $474.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology